Terms: = Ovarian cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG AND Clinical Outcome
5 results:
1. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial.
Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
[TBL] [Abstract] [Full Text] [Related]
2. Glycodelin A is a prognostic marker to predict poor outcome in advanced stage ovarian cancer patients.
Scholz C; Heublein S; Lenhard M; Friese K; Mayr D; Jeschke U
BMC Res Notes; 2012 Oct; 5():551. PubMed ID: 23036050
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma.
Verdú M; Román R; Calvo M; Rodón N; García B; González M; Vidal A; Puig X
Mod Pathol; 2011 May; 24(5):729-38. PubMed ID: 21336262
[TBL] [Abstract] [Full Text] [Related]
4. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract] [Full Text] [Related]
5. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies.
Graus F; Vega F; Delattre JY; Bonaventura I; Reñé R; Arbaiza D; Tolosa E
Neurology; 1992 Mar; 42(3 Pt 1):536-40. PubMed ID: 1312683
[TBL] [Abstract] [Full Text] [Related]
